<DOC>
	<DOC>NCT00511667</DOC>
	<brief_summary>A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or without adequate control on metformin will be sufficiently safe and well tolerated to permit continued clinical investigation.</brief_summary>
	<brief_title>A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Nonsmoking Male or Female (of nonchild bearing potential) Diagnosis of Type 2 Diabetes and is being treated with diet and exercise alone or with less than 3 oral antihyperglycemic agents Panel E only (MK0941 60 mg before 2 meals each day): diagnosis of Type 2 Diabetes and is on a dose of metformin of greater than or equal to 1500 mg for 8 weeks or more Subject is on insulin or a peroxisome proliferatoractivated receptor (PPAR) agonist Subject is on 3 or more oral antidiabetes medications Subject has a history of type 1 diabetes Subject has a diagnosis of glaucoma or is blind Subject has had trauma to one or both eyes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>